Antibody therapy for Adult T-cell leukemia-lymphoma.

  title={Antibody therapy for Adult T-cell leukemia-lymphoma.},
  author={Takashi Ishida and Ryuzo Ueda},
  journal={International journal of hematology},
  volume={94 5},
Adult T-cell leukemia-lymphoma (ATL) has a very poor prognosis. Since there currently are limited treatment options for ATL patients, several novel agents are being developed and tested clinically. Antibody therapy against ATL was initially started with interleukin-2 receptor α-subunit, CD25, as a target molecule in the late 1980s, and is currently ongoing… CONTINUE READING